1

Yi-Hsuan Wang1, Tony Eight Lin2, Yu-Cheng Chen3

  • 1Graduate Institute of Natural Products and Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Biochemical pharmacology
|December 5, 2025
PubMed
概括

研究人员确定668429化合物是甲基受体1 (FPR1) 的强有力的抑制剂,甲基受体1 (FPR1) 是中性粒细胞驱动炎症的关键标. 这种选择性抑制剂对开发用于炎症疾病的新疗法充满希望.